NasdaqGS:BCRXBiotechs
Does BioCryst’s European Navenibart Licensing Deal and Cash Infusion Change The Bull Case For BCRX?
On 4 May 2026, BioCryst Pharmaceuticals announced it had licensed European commercialization rights for its investigational HAE therapy navenibart to an Irish affiliate of Neopharmed Gentili in exchange for a US$70,000,000 upfront payment, up to US$275,000,000 in potential milestones, and tiered royalties of 18% to 30% on net sales.
This agreement deepens BioCryst’s existing relationship with Neopharmed Gentili, uses an established European rare-disease infrastructure, and brings in fresh...